Comprehensive and longitudinal study for neurodegenerative dementia using [11C]PBB3 positron emission tomography

Comprehensive and longitudinal study for neurodegenerative dementia using [11C]PBB3 positron emission tomography - Comprehensive and longitudinal study for dementia using [11C]PBB3 positron emission tomography

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000017978

Enrollment

180

Registered

2015-06-19

Start date

2015-06-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The dementia includes mild cognitive impairment, Alzheimer&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Both the disease severity and treatment is not considered for the criteria. With respect to subjects with hypertension, hyperglycemia, and hyperlipidemia, overlapping disease is approved.

Exclusion criteria

Exclusion criteria: The subject who have already took part in the previous examination in the study of dementia using [11C]PBB3 PET imaging in a year is excluded.

Design outcomes

Primary

Measure	Time frame
The association of the changes observed in amyloid imaging ([11C]PIB-PET) and tau imaging ([11C]PBB3-PET) with their clinical progression of the disease such as their cognitive decline.	—

Secondary

Measure	Time frame
The contribution of risk factor such as hypertension, hyperglycemia (diabetes), and hyperlipidemia to the cerebral amyloid/tau load or the pathophysiology of the dementia.	—

Countries

Japan

Contacts

Public ContactHitoshi Shimada

National Institute of Radiological Sciences, Molecular Neuroimaging Center Molecular Neuroimaging Program

shimada@nirs.go.jp043-206-3251

Outcome results